Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Change in Account Payables (2017 - 2019)

VYNE Therapeutics' Change in Account Payables history spans 3 years, with the latest figure at $779000.0 for Q4 2019.

  • For Q4 2019, Change in Account Payables rose 33.16% year-over-year to $779000.0; the TTM value through Dec 2019 reached $481000.0, down 41.7%, while the annual FY2019 figure was $481000.0, 41.7% down from the prior year.
  • Change in Account Payables reached $779000.0 in Q4 2019 per VYNE's latest filing, up from -$1.7 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1.6 million in Q2 2018 to a low of -$2.4 million in Q3 2018.
  • Average Change in Account Payables over 3 years is $160500.0, with a median of $682000.0 recorded in 2018.
  • The largest YoY upside for Change in Account Payables was 442.9% in 2018 against a maximum downside of 256.69% in 2018.
  • A 3-year view of Change in Account Payables shows it stood at -$1.4 million in 2017, then soared by 142.36% to $585000.0 in 2018, then soared by 33.16% to $779000.0 in 2019.
  • Per Business Quant, the three most recent readings for VYNE's Change in Account Payables are $779000.0 (Q4 2019), -$1.7 million (Q3 2019), and $921000.0 (Q2 2019).